Business Description
Biomerica Inc
NAICS : 339112
SIC : 3845
ISIN : US09061H4065
Total Employee Number:
54Description
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.92 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -15.53 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42.1 | |||||
3-Year EBITDA Growth Rate | 6.1 | |||||
3-Year EPS without NRI Growth Rate | 9.1 | |||||
3-Year FCF Growth Rate | -60.3 | |||||
3-Year Book Growth Rate | -32.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.37 | |||||
9-Day RSI | 25.55 | |||||
14-Day RSI | 28.63 | |||||
3-1 Month Momentum % | -19.27 | |||||
6-1 Month Momentum % | -25.89 | |||||
12-1 Month Momentum % | -45.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.64 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.86 | |||||
Days Inventory | 137.34 | |||||
Days Sales Outstanding | 85.93 | |||||
Days Payable | 26.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.6 | |||||
Shareholder Yield % | -25.11 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 4.32 | |||||
Operating Margin % | -123.74 | |||||
Net Margin % | -96.49 | |||||
EBITDA Margin % | -114.17 | |||||
FCF Margin % | -73.28 | |||||
OCF Margin % | -73.28 | |||||
ROE % | -92.57 | |||||
ROA % | -67.13 | |||||
ROIC % | -175.59 | |||||
3-Year ROIIC % | 37.43 | |||||
ROC (Joel Greenblatt) % | -280.47 | |||||
ROCE % | -117.16 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.93 | |||||
PB Ratio | 1.36 | |||||
Price-to-Tangible-Book | 1.46 | |||||
EV-to-EBIT | -0.65 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-Revenue | 0.8 | |||||
EV-to-FCF | -1.09 | |||||
Price-to-GF-Value | 0.68 | |||||
Price-to-Median-PS-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 1.75 | |||||
Earnings Yield (Greenblatt) % | -153.85 | |||||
FCF Yield % | -68.84 | |||||
Forward Rate of Return (Yacktman) % | 71.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BMRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomerica Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.326 | ||
| EPS (TTM) ($) | -1.58 | ||
| Beta | 1.5247 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.65 | ||
| Volatility % | 36.12 | ||
| 14-Day RSI | 28.63 | ||
| 14-Day ATR ($) | 0.072578 | ||
| 20-Day SMA ($) | 1.628165 | ||
| 12-1 Month Momentum % | -45.68 | ||
| 52-Week Range ($) | 1.465 - 4.6 | ||
| Shares Outstanding (Mil) | 3.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomerica Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomerica Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-01-14 | In 166 days | ||
| General meeting for 2026 | 2026-12-11 10:00 | In 133 days | ||
| First quarter earnings results for 2027 | 2026-10-15 | In 75 days | ||
| Annual report for 2026 | 2026-08-28 | In 27 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 27 days | ||
| Guidance call for 2026 | 2026-07-26 | 1.59 (-1.55%) | ||
| Third quarter earnings results for 2026 | 2026-04-13 | 2.13 (+0.46%) | ||
| Second quarter earnings results for 2026 | 2026-01-14 | 2.71 (+1.88%) | ||
| General meeting for 2025 | 2025-12-12 10:00 | 2.58 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-10-15 | 2.88 (+3.60%) |
Show
Entries
Biomerica Inc Frequently Asked Questions
What is Biomerica Inc(BMRA)'s stock price today?
The current price of BMRA is $1.49. The 52 week high of BMRA is $4.60 and 52 week low is $1.47.
When is next earnings date of Biomerica Inc(BMRA)?
The next earnings date of Biomerica Inc(BMRA) is 2026-08-28 Est..
Does Biomerica Inc(BMRA) pay dividends? If so, how much?
Biomerica Inc(BMRA) does not pay dividend.
Guru Commentaries on NAS:BMRA
No articles.
Press Release
Articles on Biomerica Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers